{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008765",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008765_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   decrease   the exposure to   oral   raltegravir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008766",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008766_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   increases   the exposure to   raltegravir   (high-dose) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008767",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008767_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\">Calcium carbonate</ph> <ph outputclass=\"int-magnitude\">greatly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Calcium carbonate   greatly   decreases   the exposure to   raltegravir   (high-dose) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008768",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008768_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   is predicted to   affect   the exposure to   raltegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008769",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008769_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"darunavir\" outputclass=\"int-drug\">Darunavir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of rash when given with</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Darunavir   increases   the risk of rash when given with   raltegravir .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darunavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008770",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008770_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">Encorafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Encorafenib   is predicted to   increase   the exposure to   raltegravir .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008771",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008771_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph> and <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">fosamprenavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   boosted with ritonavir   decreases   the exposure to   raltegravir  and  raltegravir   decreases   the exposure to   fosamprenavir   boosted with ritonavir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008772",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008772_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   affect   the exposure to   raltegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008773",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008773_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   affect   the exposure to   raltegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008774",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008774_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   affect   the exposure to   raltegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008775",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008775_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   affect   the exposure to   raltegravir .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008776",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008776_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid or adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   slightly   decreases   the exposure to   raltegravir .  Manufacturer advises avoid or adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008777",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008777_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sodium zirconium cyclosilicate\" outputclass=\"int-drug\">Sodium zirconium cyclosilicate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by at least 2 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sodium zirconium cyclosilicate   is predicted to   decrease   the exposure to   raltegravir .  Manufacturer advises separate administration by at least 2 hours .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium zirconium cyclosilicate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008778",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2#bnf_i1643858008778_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"raltegravir\" outputclass=\"int-heading-drug\">raltegravir</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   boosted with ritonavir   is predicted to   decrease   the exposure to   raltegravir   (high-dose) .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				}
			],
			"hasSearchLabel": " Raltegravir  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/raltegravir-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Raltegravir </title>"
			},
			"rdfs:label": "raltegravir"
		}
	]
}